Q-omics provides the consensus-scored LINC01309 profile across patient tissues and cancer cell-line models. LINC01309 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in TGCT. Among the 18 cancer types available for tumor–normal comparison, LINC01309 is differentially expressed in 2, with the highest sampling consensus in KICH. Additionally, LINC01309 RNA expression shows 6,716 significant gene co-expression associations, with the highest sampling consensus in COAD. Together, these results highlight TGCT, KICH, and COAD as cancer lineages where LINC01309 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01309 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01309 survival associations across molecular data types. LINC01309 RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01309 RNA expression–survival associations across cancer types. High LINC01309 expression shows unfavorable associations in TGCT, LUSC, ACC, THYM, LIHC and KIRP. The TGCT Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify TGCT as the clearest survival context for LINC01309 RNA expression.
This table summarizes LINC01309 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01309. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01309 shows lower tumor expression in KICH and higher tumor expression in STAD. The KICH box plot shows higher LINC01309 RNA expression in normal versus tumor tissue (log2 FC = −0.039, t-test p = .043).
This table shows molecular features associated with LINC01309 in patient tissues and cancer cell lines. In patient samples, LINC01309 shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set.
